83 related articles for article (PubMed ID: 20186542)
1. 131I treatment of thyroid papillary carcinoma in a patient with renal failure.
Morrish DW; Filipow LJ; McEwan AJ; Schmidt R; Murland KR; von Westarp C; Betcher KB
Cancer; 1990 Dec; 66(12):2509-13. PubMed ID: 2249192
[TBL] [Abstract][Full Text] [Related]
2. Molecular radiotheragnostics in thyroid disease.
Singh N; Lewington V
Clin Med (Lond); 2017 Oct; 17(5):453-457. PubMed ID: 28974598
[TBL] [Abstract][Full Text] [Related]
3. Radionuclide therapy.
Bomanji JB
Clin Med (Lond); 2006; 6(3):249-53. PubMed ID: 16826856
[No Abstract] [Full Text] [Related]
4. Choosing the Right Metrics for Evaluation of Radiopharmaceutical Therapy Dosimetry Methodologies.
Scheuermann JS; Pryma DA
J Nucl Med; 2023 Oct; 64(10):1617-1618. PubMed ID: 37788852
[No Abstract] [Full Text] [Related]
5. Investigation of the Suitability of a Commercial Radiation Sensor for Pretherapy Dosimetry of Radioiodine Treatment Patients.
O'Callaghan J; Cody D; Cooke J
Sensors (Basel); 2022 Dec; 22(23):. PubMed ID: 36502094
[TBL] [Abstract][Full Text] [Related]
6. Gender differences in estimating I-131 thyroid uptake from Tc-99m thyroid uptake for benign thyroid disease.
Al-Jabri A; Cooke J; Cournane S; Healy ML
Br J Radiol; 2021 Feb; 94(1118):20200700. PubMed ID: 33242250
[TBL] [Abstract][Full Text] [Related]
7. Nine Genes Mediate the Therapeutic Effects of Iodine-131 Radiotherapy in Thyroid Carcinoma Patients.
Shuwen H; Xi Y; Miao D; Jiamin X; Jing Z; Weili G
Dis Markers; 2020; 2020():9369341. PubMed ID: 32626543
[TBL] [Abstract][Full Text] [Related]
8. Red bone marrow dose estimation using several internal dosimetry models for prospective dosimetry-oriented radioiodine therapy.
Abuqbeitah M; Demir M; Çavdar İ; Tanyildizi H; Yeyin N; Uslu-Beşli L; Kabasakal L; Işıkcı Nİ; Sönmezoğlu K
Radiat Environ Biophys; 2018 Nov; 57(4):395-404. PubMed ID: 30298289
[TBL] [Abstract][Full Text] [Related]
9. Comparing pre-therapeutic
Gühne F; Kühnel C; Freesmeyer M
Endocrine; 2017 Apr; 56(1):43-53. PubMed ID: 28271395
[TBL] [Abstract][Full Text] [Related]
10. The "reset button" revisited: why high activity
Verburg FA; Luster M; Giovanella L; Lassmann M; Chiesa C; Chouin N; Flux G;
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):915-917. PubMed ID: 28210770
[No Abstract] [Full Text] [Related]
11. Personalized Medicine Based on Theranostic Radioiodine Molecular Imaging for Differentiated Thyroid Cancer.
Ahn BC
Biomed Res Int; 2016; 2016():1680464. PubMed ID: 27239470
[TBL] [Abstract][Full Text] [Related]
12. The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy.
Strigari L; Konijnenberg M; Chiesa C; Bardies M; Du Y; Gleisner KS; Lassmann M; Flux G
Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1976-88. PubMed ID: 24915892
[TBL] [Abstract][Full Text] [Related]
13. EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry II. Dosimetry prior to radioiodine therapy of benign thyroid diseases.
Hänscheid H; Canzi C; Eschner W; Flux G; Luster M; Strigari L; Lassmann M
Eur J Nucl Med Mol Imaging; 2013 Jul; 40(7):1126-34. PubMed ID: 23576099
[TBL] [Abstract][Full Text] [Related]
14. Exhalation of ¹³¹I after radioiodine therapy: measurements in exhaled air.
Schomäcker K; Sudbrock F; Fischer T; Dietlein M; Kobe C; Gaidouk M; Schicha H
Eur J Nucl Med Mol Imaging; 2011 Dec; 38(12):2165-72. PubMed ID: 21847636
[TBL] [Abstract][Full Text] [Related]
15. EANM procedure guidelines for therapy of benign thyroid disease.
Stokkel MP; Handkiewicz Junak D; Lassmann M; Dietlein M; Luster M
Eur J Nucl Med Mol Imaging; 2010 Nov; 37(11):2218-28. PubMed ID: 20625722
[TBL] [Abstract][Full Text] [Related]
16. Radioiodine therapy dosimetry in benign thyroid disease and differentiated thyroid carcinoma.
Salvatori M; Luster M
Eur J Nucl Med Mol Imaging; 2010 Apr; 37(4):821-8. PubMed ID: 20186542
[No Abstract] [Full Text] [Related]
17. [Controversies in the follow-up and management of well-differentiated thyroid cancer. New answers to old questions].
Abós Olivares MD; Pesquera González C
Rev Esp Med Nucl; 2005; 24(3):207-15. PubMed ID: 15847791
[No Abstract] [Full Text] [Related]
18. Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET.
Eschmann SM; Reischl G; Bilger K; Kupferschläger J; Thelen MH; Dohmen BM; Besenfelder H; Bares R
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):760-7. PubMed ID: 12029549
[TBL] [Abstract][Full Text] [Related]
19. Radioiodine therapy for papillary and follicular thyroid carcinoma.
Klain M; Ricard M; Leboulleux S; Baudin E; Schlumberger M
Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S479-85. PubMed ID: 12192549
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
